In the GREACE (Greek Atorvastatin and Coronary Heart Disease Evaluation) study, 1600 patients with coronary heart disease were randomized to atorvastatin or usual care; of these, 437 had moderately abnormal liver tests at baseline, suggesting non-alcoholic fatty liver disease (NAFLD). In a post-hoc analysis of this subset of patients, published in the Lancet, the GREACE…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.